Anticonvulsive properties of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor-Reference-Cited by-同舟云学术

Anticonvulsive properties of soticlestat, a novel cholesterol 24‐hydroxylase inhibitor

Published:2022-03-30 Issue:6 Volume:63 Page:1580-1590
ISSN:0013-9580
Container-title:Epilepsia
language:en
Short-container-title:Epilepsia

Author:

Nishi Toshiya¹^ORCID,Metcalf Cameron S.²^ORCID,Fujimoto Shinji¹,Hasegawa Shigeo¹,Miyamoto Maki¹,Sunahara Eiji¹,Watanabe Sayuri¹,Kondo Shinichi¹,White H. Steve³

Affiliation:

1. Neuroscience Drug Discovery Unit Takeda Pharmaceutical Company Limited Fujisawa Japan

2. Department of Pharmacology and Toxicology College of Pharmacy University of Utah Salt Lake City Utah USA

3. Department of Pharmacy School of Pharmacy University of Washington Seattle Washington USA

Funder

Takeda Pharmaceutical Company

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/epi.17232

Reference48 articles.

1. Outsourcing in the brain: Do neurons depend on cholesterol delivery by astrocytes?

2. Thematic review series: Brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal

3. The lipid habitats of neurotransmitter receptors in brain;Borroni MV;Biochim Biophys Acta,1858

4. Knockout of the Cholesterol 24-Hydroxylase Gene in Mice Reveals a Brain-specific Mechanism of Cholesterol Turnover

5. Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis;Expert Opinion on Drug Discovery;2024-07-29

2. New epilepsy therapies in development;Nature Reviews Drug Discovery;2024-07-22

3. Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function;Pharmacology Research & Perspectives;2024-07-11

4. Unbiased insights into the multiplicity of the CYP46A1 brain effects in 5XFAD mice treated with low dose-efavirenz;Journal of Lipid Research;2024-06

5. Characterization of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in acute and chronic neurodegeneration models;Neuroscience Research;2024-06